Rain Oncology Inc. Research and Development Expense
Rain Oncology Inc. reported Research and Development Expense of $3.96 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-09
- Rain Oncology Inc. research and development expense for the quarter ending 2023-09-30 was $3.96M, a 72.67% decline year-over-year.
- Rain Oncology Inc. research and development expense for the quarter ending 2023-06-30 was $14.98M, a 5.07% increase year-over-year.
- Rain Oncology Inc. research and development expense for the quarter ending 2023-03-31 was $16.68M, a 23.03% increase year-over-year.
- Rain Oncology Inc. research and development expense for the quarter ending 2022-12-31 was $19.08M, a 30.03% increase year-over-year.
- Rain Oncology Inc. research and development expense for fiscal 2022 was $61.40M, a 50.59% increase from fiscal 2021.
- Rain Oncology Inc. research and development expense for fiscal 2021 was $40.77M, a 165.33% increase from fiscal 2020.
- Rain Oncology Inc. research and development expense for fiscal 2020 was $15.37M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $3.96M 10-Q · filed 2023-11-09 | $18.95M derived: sum of 2 quarters · filed 2023-11-09 | $35.62M 10-Q · filed 2023-11-09 | $54.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $14.98M 10-Q · filed 2023-08-10 | $31.66M 10-Q · filed 2023-08-10 | $50.73M derived: sum of 3 quarters · filed 2023-08-10 | $65.25M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | $16.68M 10-Q · filed 2023-05-11 | $35.76M derived: sum of 2 quarters · filed 2023-05-11 | $50.27M derived: sum of 3 quarters · filed 2023-11-09 | $64.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | $19.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $33.59M derived: sum of 2 quarters · filed 2023-11-09 | $47.84M derived: sum of 3 quarters · filed 2023-11-09 | $61.40M 10-K · filed 2023-03-09 |
| 2022-09-30 | $14.51M 10-Q · filed 2023-11-09 | $28.77M derived: sum of 2 quarters · filed 2023-11-09 | $42.32M 10-Q · filed 2023-11-09 | $56.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $14.26M 10-Q · filed 2023-08-10 | $27.81M 10-Q · filed 2023-08-10 | $42.48M derived: sum of 3 quarters · filed 2023-08-10 | $57.77M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.55M 10-Q · filed 2023-05-11 | $28.23M derived: sum of 2 quarters · filed 2023-05-11 | $43.51M derived: sum of 3 quarters · filed 2023-05-11 | $49.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $29.96M derived: sum of 2 quarters · filed 2023-03-09 | $35.45M derived: sum of 3 quarters · filed 2023-03-09 | $40.77M 10-K · filed 2023-03-09 |
| 2021-09-30 | $15.28M 10-Q · filed 2022-11-10 | $20.77M derived: sum of 2 quarters · filed 2022-11-10 | $26.10M 10-Q · filed 2022-11-10 | $30.27M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.49M 10-Q · filed 2022-08-04 | $10.82M 10-Q · filed 2022-08-04 | $14.99M derived: sum of 3 quarters · filed 2022-08-04 | $22.88M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $5.33M 10-Q · filed 2022-05-04 | $9.50M derived: sum of 2 quarters · filed 2022-05-04 | $17.39M derived: sum of 3 quarters · filed 2022-05-04 | $18.87M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $12.06M derived: sum of 2 quarters · filed 2022-03-03 | $13.54M derived: sum of 3 quarters · filed 2022-03-03 | $15.37M 10-K · filed 2022-03-03 |
| 2020-09-30 | $7.89M 10-Q · filed 2021-11-10 | $9.37M derived: sum of 2 quarters · filed 2021-11-10 | $11.20M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.47M 10-Q · filed 2021-08-10 | $3.23M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $1.76M 10-Q · filed 2021-05-25 |